Aisha Zhantleuova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aisha Zhantleuova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bazbek Davletov
Department of Biomedical Science, University of Sheffield, Sheffield, UK
2 shared publications Ahmed Dahshan
Department of Neurology, Cairo University, Cairo, Egypt
1 shared publicationAltynay Karimova
Al-Farabi Kazakh National University
1 shared publication- Altynay Karimova
Department of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, Almaty A15E3C7, Kazakhstan
1 shared publication - Anna P. Andreou
Headache Research, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE1 1UL, UK
1 shared publication Asel Jusupova
Department of Neurology and Clinical Genetics, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
1 shared publication
Latest Publications
- Open Access
- 10 September 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (9)
Are we closer to achieving precision medicine for migraine treatment? A narrative review
Background: The term ‘precision medicine’ encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of multifaceted datasets and strategies to model such data have made precision medicine increasingly possible in recent years. Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine. Objective: To provide a narrative review describing contributions to achieving precision medicine for migraine treatment. Methods: A search of PubMed for English language articles of human participants published from 2005 to January 2024 was conducted to identify articles that reported research contributing to precision medicine for migraine treatment. The published literature was categorized and summarized according to the type of data that were included: clinical phenotypes, genomics, proteomics, physiologic measures, and brain imaging. Results: Published studies have investigated characteristics associated with acute and preventive treatment responses, such as nonsteroidal anti-inflammatory drugs, triptans, onabotulinumtoxinA, and anti-calcitonin gene-related peptide monoclonal antibodies, in patients with episodic or chronic migraine. There is evidence that clinical, genetic, epigenetic, proteomic, physiologic, and brain imaging features might associate with migraine treatment outcomes, although inconsistencies for such findings clearly exist. Conclusions: The published literature suggests that there are clinical and biological features which associate with, and might be useful for predicting, migraine treatment responses. To achieve precision medicine for migraine treatment, further research is needed that validates and expands on existing findings and tests the accuracy and value of migraine treatment prediction models in clinical settings.
- 10 September 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (9)
Open AccessAre we closer to achieving precision medicine for migraine treatment? A narrative review
Background: The term ‘precision medicine’ encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of multifaceted datasets and strategies to model such data have made precision medicine increasingly possible in recent years. Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine. Objective: To provide a narrative review describing contributions to achieving precision medicine for migraine treatment. Methods: A search of PubMed for English language articles of human participants published from 2005 to January 2024 was conducted to identify articles that reported research contributing to precision medicine for migraine treatment. The published literature was categorized and summarized according to the type of data that were included: clinical phenotypes, genomics, proteomics, physiologic measures, and brain imaging. Results: Published studies have investigated characteristics associated with acute and preventive treatment responses, such as nonsteroidal anti-inflammatory drugs, triptans, onabotulinumtoxinA, and anti-calcitonin gene-related peptide monoclonal antibodies, in patients with episodic or chronic migraine. There is evidence that clinical, genetic, epigenetic, proteomic, physiologic, and brain imaging features might associate with migraine treatment outcomes, although inconsistencies for such findings clearly exist. Conclusions: The published literature suggests that there are clinical and biological features which associate with, and might be useful for predicting, migraine treatment responses. To achieve precision medicine for migraine treatment, further research is needed that validates and expands on existing findings and tests the accuracy and value of migraine treatment prediction models in clinical settings.
- Open Access
Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications
This review discusses the expanding application of botulinum neurotoxin in treating neurological conditions. The article specifically explores novel approaches to using non-paralytic botulinum molecules. These new molecules, such as BiTox or el-iBoNT, offer an alternative for patients who face limitations in using paralytic forms of botulinum neurotoxin due to concerns about muscle function loss. We highlight the research findings that confirm not only the effectiveness of these molecules but also their reduced paralytic effect. We also discuss a potential cause for the diminished paralytic action of these molecules, specifically changes in the spatial parameters of the new botulinum molecules. In summary, this article reviews the current research that enhances our understanding of the application of new botulinum neurotoxins in the context of common conditions and suggests new avenues for developing more efficient molecules.
Open AccessRecent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications
This review discusses the expanding application of botulinum neurotoxin in treating neurological conditions. The article specifically explores novel approaches to using non-paralytic botulinum molecules. These new molecules, such as BiTox or el-iBoNT, offer an alternative for patients who face limitations in using paralytic forms of botulinum neurotoxin due to concerns about muscle function loss. We highlight the research findings that confirm not only the effectiveness of these molecules but also their reduced paralytic effect. We also discuss a potential cause for the diminished paralytic action of these molecules, specifically changes in the spatial parameters of the new botulinum molecules. In summary, this article reviews the current research that enhances our understanding of the application of new botulinum neurotoxins in the context of common conditions and suggests new avenues for developing more efficient molecules.
- Open Access
- 1 March 2024
- Published by al-Farabi Kazakh National University in Experimental Biology
- Vol. 98 (1) , 154-166
USE OF RAT GRIMACE SCALE IN PAIN RESEARCH
Since its introduction in 2011, the rat grimace scale has become a valuable tool for pain assessment in preclinical studies. In our article, we provide an overview of a variety of studies in which this method has been applied in surgical and postoperative pain models, inflammatory pain models, orthodontic and orofacial pain models, neuropathic pain, and others. In addition, we present the results of pain assessment in rats with nitroglycerin-induced migraine. Although the scale covers four functional units, our findings suggest that orbital tightening is preferred in the migraine model as the functional unit that best fits the features of this model. An interesting direction is the prospect of using artificial intelligence technologies for automatic pain grimace recognition and data analysis. This innovative approach promises to significantly reduce the time and resource costs of image evaluation, and improve the accuracy of the estimates by eliminating the subjectivity associated with human evaluations. С момента своего внедрения в 2011 году, шкала гримасы крыс стала ценным инструментом для оценки боли в преклинических исследованиях. В нашей статье мы предоставляем обзор разнообразных исследований, в которых данный метод применялся в хирургических и послеоперационных моделях боли, воспалительных моделях боли, ортодонтических и орофациальных моделях боли, невропатических моделях боли и других. Кроме того, мы представляем результаты оценки боли у крыс с нитроглицерин-индуцированной мигренью. Несмотря на то, что шкала охватывает четыре функциональных юнита, наши выводы указывают на то, что в модели мигрени предпочтительнее использовать орбитальное сужение, как функциональный юнит, наилучшим образом соответствующих особенностям данной модели. Интересным направлением является перспектива использования технологий искусственного интеллекта для автоматического распознавания болевой гримасы и анализа данных. Этот инновационный подход обещает существенно сократить временные и ресурсные затраты на оценку изображений, а также повысить точность оценок, исключив субъективность, связанную с оценками, проводимыми человеком. 2011 жылы енгізілгеннен бастап, егеуқұйрықтардың бет-әлпеті шкаласы клиникаға дейінгі зерттеулердегі ауырсынуды бағалаудың құнды құралына айналды. Біздің мақалада біз бұл әдіс хирургиялық және операциядан кейінгі ауырсыну үлгілерінде, қабыну ауруы үлгілерінде, ортодонтиялық және ауыз-бет ауруы үлгілерінде, невропатиялық ауырсынуда және т.б. қолданылған әртүрлі зерттеулерге шолу жасаймыз. Сонымен қатар, біз нитроглицеринмен индукцияланған мигрень егеуқұйрықтарындағы ауырсынуды бағалау нәтижелерін ұсынамыз. Масштаб төрт функционалды бірлікті қамтығанына қарамастан, біздің қорытындыларымыз мигрень моделінде берілген модельдің ерекшеліктеріне сәйкес келетін функционалды бірлік ретінде орбиталық тарылуды қолданған жөн екенін көрсетеді. Қызықты бағыт-ауырсынуды автоматты түрде тану және деректерді талдау үшін жасанды интеллект технологияларын қолдану перспективасы. Бұл инновациялық тәсіл кескінді бағалауға кететін уақыт пен ресурстық шығындарды айтарлықтай азайтуға, сондай-ақ адам жүргізетін бағалаулармен байланысты субъективтілікті жоққа шығару арқылы бағалаудың дәлдігін арттыруға уәде береді.
- 1 March 2024
- Published by al-Farabi Kazakh National University in Experimental Biology
- Vol. 98 (1) , 154-166
Open AccessUSE OF RAT GRIMACE SCALE IN PAIN RESEARCH
Since its introduction in 2011, the rat grimace scale has become a valuable tool for pain assessment in preclinical studies. In our article, we provide an overview of a variety of studies in which this method has been applied in surgical and postoperative pain models, inflammatory pain models, orthodontic and orofacial pain models, neuropathic pain, and others. In addition, we present the results of pain assessment in rats with nitroglycerin-induced migraine. Although the scale covers four functional units, our findings suggest that orbital tightening is preferred in the migraine model as the functional unit that best fits the features of this model. An interesting direction is the prospect of using artificial intelligence technologies for automatic pain grimace recognition and data analysis. This innovative approach promises to significantly reduce the time and resource costs of image evaluation, and improve the accuracy of the estimates by eliminating the subjectivity associated with human evaluations. С момента своего внедрения в 2011 году, шкала гримасы крыс стала ценным инструментом для оценки боли в преклинических исследованиях. В нашей статье мы предоставляем обзор разнообразных исследований, в которых данный метод применялся в хирургических и послеоперационных моделях боли, воспалительных моделях боли, ортодонтических и орофациальных моделях боли, невропатических моделях боли и других. Кроме того, мы представляем результаты оценки боли у крыс с нитроглицерин-индуцированной мигренью. Несмотря на то, что шкала охватывает четыре функциональных юнита, наши выводы указывают на то, что в модели мигрени предпочтительнее использовать орбитальное сужение, как функциональный юнит, наилучшим образом соответствующих особенностям данной модели. Интересным направлением является перспектива использования технологий искусственного интеллекта для автоматического распознавания болевой гримасы и анализа данных. Этот инновационный подход обещает существенно сократить временные и ресурсные затраты на оценку изображений, а также повысить точность оценок, исключив субъективность, связанную с оценками, проводимыми человеком. 2011 жылы енгізілгеннен бастап, егеуқұйрықтардың бет-әлпеті шкаласы клиникаға дейінгі зерттеулердегі ауырсынуды бағалаудың құнды құралына айналды. Біздің мақалада біз бұл әдіс хирургиялық және операциядан кейінгі ауырсыну үлгілерінде, қабыну ауруы үлгілерінде, ортодонтиялық және ауыз-бет ауруы үлгілерінде, невропатиялық ауырсынуда және т.б. қолданылған әртүрлі зерттеулерге шолу жасаймыз. Сонымен қатар, біз нитроглицеринмен индукцияланған мигрень егеуқұйрықтарындағы ауырсынуды бағалау нәтижелерін ұсынамыз. Масштаб төрт функционалды бірлікті қамтығанына қарамастан, біздің қорытындыларымыз мигрень моделінде берілген модельдің ерекшеліктеріне сәйкес келетін функционалды бірлік ретінде орбиталық тарылуды қолданған жөн екенін көрсетеді. Қызықты бағыт-ауырсынуды автоматты түрде тану және деректерді талдау үшін жасанды интеллект технологияларын қолдану перспективасы. Бұл инновациялық тәсіл кескінді бағалауға кететін уақыт пен ресурстық шығындарды айтарлықтай азайтуға, сондай-ақ адам жүргізетін бағалаулармен байланысты субъективтілікті жоққа шығару арқылы бағалаудың дәлдігін арттыруға уәде береді.
- Open Access
- 7 July 2023
- Published by Wiley
Beyond Aesthetics: Expanding Applications of Botulinum Neurotoxins in Chronic Migraine Medicine
This article discusses the expanding application of botulinum neurotoxin in treating chronic migraines beyond aesthetic purposes. Special attention is given to the mechanisms underlying the therapeutic action of this treatment, namely, the blockade of neurotransmitter releases responsible for pain signal transmission, modulation of nociceptors, and its effects on the central nervous system. The article provides an analysis of existing literature, including preclinical and clinical data, to evaluate the efficacy and safety of using botulinum neurotoxin for the prevention and treatment of chronic migraine attacks. Additionally, the article explores novel approaches to using non-paralyzing botulinum molecules in the context of chronic migraines. These new molecules, such as Bitox or el-iBoNT, offer an alternative for patients who face limitations in using paralyzing forms of botulinum neurotoxin due to concerns about muscle function loss. The authors highlight research findings that confirm not only the effectiveness of these molecules in controlling chronic pain but also a reduced paralytic effect. The authors also discuss a potential cause for the diminished paralytic action of these molecules, specifically changes in the stereoisomeric parameters of the treatment. In summary, this article reviews current research that enhances our understanding of the application of botulinum neurotoxin in the context of chronic migraines and opens avenues for developing new, more efficient molecules for treating this condition.
- 7 July 2023
- Published by Wiley
Open AccessBeyond Aesthetics: Expanding Applications of Botulinum Neurotoxins in Chronic Migraine Medicine
This article discusses the expanding application of botulinum neurotoxin in treating chronic migraines beyond aesthetic purposes. Special attention is given to the mechanisms underlying the therapeutic action of this treatment, namely, the blockade of neurotransmitter releases responsible for pain signal transmission, modulation of nociceptors, and its effects on the central nervous system. The article provides an analysis of existing literature, including preclinical and clinical data, to evaluate the efficacy and safety of using botulinum neurotoxin for the prevention and treatment of chronic migraine attacks. Additionally, the article explores novel approaches to using non-paralyzing botulinum molecules in the context of chronic migraines. These new molecules, such as Bitox or el-iBoNT, offer an alternative for patients who face limitations in using paralyzing forms of botulinum neurotoxin due to concerns about muscle function loss. The authors highlight research findings that confirm not only the effectiveness of these molecules in controlling chronic pain but also a reduced paralytic effect. The authors also discuss a potential cause for the diminished paralytic action of these molecules, specifically changes in the stereoisomeric parameters of the treatment. In summary, this article reviews current research that enhances our understanding of the application of botulinum neurotoxin in the context of chronic migraines and opens avenues for developing new, more efficient molecules for treating this condition.